Expression of the epidermal growth factor system in endometrial cancer

The aim of our study was to describe the expression of c-erbB-1. c-erbB-2, c-erbB-3 and c-erbB-4 in endometrial cancer tissue and its correlation with clinicopathologic features and prognosis of the patients. One hundred and six cases of endometrial cancer were identified from the archives of the Department of Obstetrics and Gynecology of the University of Patras. Tissue specimens from endometrial lesions were immunostained for c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4. Statistical analyses were performed using the chi square test, Kaplan-Meier method and Cox analysis. We found a significant association between c-erbB-1 expression and patient survival. A reverse correlation was found between tumor grade and c-erbB-1 expression. Tumor grade was not significantly correlated with the expression of the remaining three receptors. Stage of the tumor showed no relationship with the expression of these receptors. The ability to predict increased risks of advanced disease. recurrence. and death from abnormal molecular markers detected ill curettage or endometrial biopsy specimens will facilitate pretreatment referral of these patients to gynecologic oncologists for definitive surgical treatment.

Endometrial cancer; EGF system; c-erbB receptors; Prognosis

[1] Jemal A., Thomas A., Murray T., Thun M.: “Cancer statistics, 2002”. CA Cancer J. Clin., 2002, 52, 23.

[2] Parazzini F., La Vecchia C., Bocciolone L., Francheschi S.: “The epidemiology of endometrial cancer”. Gynecol. Oncol., 1991, 41, 1.

[3] Alroy I., Yarden Y.: “The ErbB signalling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions”. FEBS Lett., 1997, 410, 83.

[4] Harris R.C., Chung E., Coffey R.J.: “EGF receptor ligands”. Exp. Cell. Res., 2003, 284, 2.

[5] Marmor M.D., Skaria K.B., Yarden Y.: “Signal transduction and oncogenesis by ErbB/HER receptors”. Int. J. Radiat. Oncol. Biol. Phys., 2004, 58, 903.

[6] Imai T., Kurachi H., Adachi K., Adachi H., Yashimoto Y., Homma H. et al.: “Changes in epidermal growth factor receptor and the levels of its ligands during menstrual cycle in human endometrium”. Biol. Reprod., 1995, 52, 928.

[7] Srinivasan R., Benton E., McCormick F., Thomas H., Gullick W.J.: “Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer”. Clin. Cancer Res., 1999, 5, 2877.

[8] Chobotova K., Karpovich N., Carver J., Manek S., Gullick W.J., Barlow D.H. et al.: “Heparin-binding epidermal growth factor in the human endometrium is mediated by the epidermal growth factors mediate decidualization and potentiate survival of human endometrial stromal cells”. J. Clin. Endocrinol. Metab., 2005, 90, 913.

[9] Ejskjaer K., Sorensen B., Poulsen S., Mogensen O., Forman A., Nexo E.: “Expression of the epidermal growth factor system in human endometrium during the menstrual cycle”. Mol. Hum. Reprod., 2005, 11, 543.

[10] Moller B., Rasmussen C., Lindblom B., Olovsson M.: “Expression of the angiogenic growth factors VEGF, FGF-2, EGF and their receptors in normal human endometrium during the menstrual cycle”. Mol. Hum. Reprod., 2001, 7, 65.

[11] Rasheed B.K., Wiltshire R.N., Bigner S.H., Bigner D.D.: “Molecular pathogenesis of malignant gliomas”. Curr. Opin. Oncol., 1999, 11, 162.

[12] Schaefer G., Akita R.W., Sliwkowski M.X.: “A discrete threeamino acid segment (LVI) at the C-terminal end of kinaseimpaired ErbB3 is required for transactivation of ErbB2”. J. Biol. Chem., 1999, 274, 859.

[13] Casalini P., Iorio M.V., Gamozzi E., Menard S.: “Role of HER receptors family in development and differentiation”. J. Cell. Physiol., 2004, 200, 343.

[14] Wright C., Angus B., Nicholson S., Sainsbury J.R., Cairns J., Gullick W.J. et al.: “Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer”. Cancer Res., 1989, 49, 2087.

[15] Costa M.J., Walls J.: “Epidermal growth factor receptor and cerbB- 2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed mullerian tumors). Clinicopathologic study of 82 cases”. Cancer, 1996, 77, 533.

[16] Yonemura Y., Sugiyama K., Fushida S., Kamata T., Ohoyama S., Kimura H. et al.: “Tissue status of epidermal growth factor and its receptor as an indicator of poor prognosis in patients with gastric cancer”. Anal. Cell. Pathol., 1991, 3, 343.

[17] Saffari B., Jones L.A., el-Naggar A., Felix J.C., George J., Press M.F.: “Amplification and overexpression of HER-2/neu (c-erbB-2) in endometrial cancers: correlation with overall survival”. Canc Res., 1995, 55, 5693.

[18] Pisani A.L., Barbuto D.A., Chen D., Ramos L., Lagasse L.D., Karlan B.Y.: “HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma”. Obstet. Gynecol., 1995, 85, 729.

[19] Tzahar E., Levkowitz G., Karunagaran D., Yi L., Peles E., Lavi S. et al.: “ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms”. J. Biol. Chem., 1994, 269, 25226.

[20] Kato T.: “Expression of mRNA for heregulin and its receptor, erbB-3 and erbB-4 in human upper gastrointestinal mucosa”. Life Sc., 1998, 63, 553.

[21] Kraus M.H., Issing W., Miki T., Popescu N.C., Aaronson S.A.: “Isolation and characterization of erbB-3, a third member of the ErbB/epidermal growth factor family: evidence for overexpression in a subset of human mammary tumors”. Proc. Natl. Acad. Sci USA, 1989, 86, 9193.

[22] Srinivasan R., Poulsom R., Hurst H.C., Gullick W.J.: “Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types”. J. Pathol., 1998, 185, 236.